Sellas Life Sciences Group (ehemals Galena Biopharma) (Seite 234)
eröffnet am 30.10.12 22:43:19 von
neuester Beitrag 19.01.24 22:21:17 von
neuester Beitrag 19.01.24 22:21:17 von
Beiträge: 2.935
ID: 1.177.530
ID: 1.177.530
Aufrufe heute: 0
Gesamt: 345.724
Gesamt: 345.724
Aktive User: 0
ISIN: US81642T2096 · WKN: A2PU3T · Symbol: RXK3
1,3600
EUR
-4,09 %
-0,0580 EUR
Letzter Kurs 26.04.24 Tradegate
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,9000 | +305,04 | |
| 1,2200 | +80,74 | |
| 0,6080 | +26,25 | |
| 6,0000 | +25,00 | |
| 0,6400 | +18,52 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,1200 | -12,17 | |
| 8,5000 | -15,00 | |
| 0,7300 | -18,59 | |
| 92,06 | -19,84 | |
| 2,7280 | -29,14 |
Beitrag zu dieser Diskussion schreiben
FeedbackZitat von Aurum2010:Zitat von lunatics: Das ist normal bei einem Unternehmen das noch Verlust schreibt. Da bedeuten Zahlen nichts.
Verlust ist klar aber GALE hatte einen unerwartet satten, so dass schneller als gedacht / geplant wieder neue Shares herausgegeben werden müssen. Zudem hat sich Abstral Umsatztechnisch nicht wie erwartet entwickelt... Ich bleibe dennoch dabei.
Denke auch der schwache Ausblick zu Abstral hält GALE unter Druck...
Zudem die SEC Geschichte welche noch hängig ist sowie, dass nach den massiven Insiderverkäufen keine Käufe erfolgt sind. GALE hat noch ne Menge Unsicherheiten bzw. Risiken
Zitat von lunatics: Das ist normal bei einem Unternehmen das noch Verlust schreibt. Da bedeuten Zahlen nichts.
Verlust ist klar aber GALE hatte einen unerwartet satten, so dass schneller als gedacht / geplant wieder neue Shares herausgegeben werden müssen. Zudem hat sich Abstral Umsatztechnisch nicht wie erwartet entwickelt... Ich bleibe dennoch dabei.
Das ist normal bei einem Unternehmen das noch Verlust schreibt. Da bedeuten Zahlen nichts.
Die GALE Q2 Zahlen wurden nicht gut aufgenommen, GALE hat seit Montag ca. 18% eingebüst...
Trading Spotlight
Second Quarter 2014 Financial Highlights
Net revenue for the three months ended June 30, 2014 was $2.3 million and $4.5 million for the first half of 2014, compared to no net revenue for the six months ended June 30, 2013. Cost of revenue and gross margin were $0.3 million and $2.0 million, respectively, for the three months ended June 30, 2014. Of the net revenue, approximately $0.9 million was attributable to an order from one of the principal customers of Galena. The timing and amount of the order could cause a corresponding reduction in orders from this customer, and in related revenue, in the third quarter of 2014.
Operating loss for the three months ended June 30, 2014 was $15.8 million, including $1.5 million in stock-based compensation charges, compared to $11.8 million, including $1.7 million in stock-based compensation charges, for the three months ended March 31, 2014, and $8.0 million, including $0.5 million in stock-based compensation charges, for the three months ended June 30, 2013.
Galena also incurs non-cash income and expense related to changes in the fair value estimates of the Company's warrant liabilities. Non-cash expense related to the change in warrant values for the three months ended June 30, 2014 was $3.4 million compared to non-cash income of $9.8 million for the three months ended March 31, 2014, and non-cash expense of $0.5 million for the three months ended June 30, 2013.
Net loss for the three months ended June 30, 2014 was $19.9 million, or $0.17 per basic and diluted share, compared to a net loss of $2.5 million, or $0.02 per basic and diluted share, for the three months ended March 31, 2014, and a net loss of $9.6 million, or $0.11 per basic and diluted share, for the three months ended June 30, 2013.
As of June 30, 2014, Galena had cash and cash equivalents of $39.2 million, compared with $47.8 million as of December 31, 2013.
quelle: finace.yahoo.com
Net revenue for the three months ended June 30, 2014 was $2.3 million and $4.5 million for the first half of 2014, compared to no net revenue for the six months ended June 30, 2013. Cost of revenue and gross margin were $0.3 million and $2.0 million, respectively, for the three months ended June 30, 2014. Of the net revenue, approximately $0.9 million was attributable to an order from one of the principal customers of Galena. The timing and amount of the order could cause a corresponding reduction in orders from this customer, and in related revenue, in the third quarter of 2014.
Operating loss for the three months ended June 30, 2014 was $15.8 million, including $1.5 million in stock-based compensation charges, compared to $11.8 million, including $1.7 million in stock-based compensation charges, for the three months ended March 31, 2014, and $8.0 million, including $0.5 million in stock-based compensation charges, for the three months ended June 30, 2013.
Galena also incurs non-cash income and expense related to changes in the fair value estimates of the Company's warrant liabilities. Non-cash expense related to the change in warrant values for the three months ended June 30, 2014 was $3.4 million compared to non-cash income of $9.8 million for the three months ended March 31, 2014, and non-cash expense of $0.5 million for the three months ended June 30, 2013.
Net loss for the three months ended June 30, 2014 was $19.9 million, or $0.17 per basic and diluted share, compared to a net loss of $2.5 million, or $0.02 per basic and diluted share, for the three months ended March 31, 2014, and a net loss of $9.6 million, or $0.11 per basic and diluted share, for the three months ended June 30, 2013.
As of June 30, 2014, Galena had cash and cash equivalents of $39.2 million, compared with $47.8 million as of December 31, 2013.
quelle: finace.yahoo.com
Heute wieder Rekordkäufe zu Beginn des Handels.
Decken sich die Konzernchefs von Roche schon ein?
Decken sich die Konzernchefs von Roche schon ein?
Bei Gale wird gekauft was das Zeug hält.
Da sind sich wieder einige sehr sicher für Montag
Da sind sich wieder einige sehr sicher für Montag
GALE will Zuplenz zu ein Blockbuster machen.
Jüngst wurden die US-Vermarktungsrechte für 5 Mio. gekauft.
Jüngst wurden die US-Vermarktungsrechte für 5 Mio. gekauft.
Galena Biopharma to Report Second Quarter 2014 Financial Results on Monday, August 11, 2014 atc.
Durchsuchen
